Brought to you by 
Lexicon Genetics acquires Coelacanth
26 Jul 2001
Executive Summary
Lexicon Genetics (functional genomics) has acquired 100% of the stock in private biotech company Coelacanth Corp. (combinatorial chemistry). The transaction, which includes a collar provision, is expected to close by the end of July.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lexicon Genetics acquires Coelacanth
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice